Change Notification UK National Blood Services No. 32 - 2020

Provisional Component: Red Cells and Plasma, Leucocyte Depleted


Please make the following changes to section A3.5.1 of A3.5 Red Cells and Plasma, Leucocyte Depleted

A3.5.1: Technical information

- Red Cells and Plasma, Leucocyte Depleted (LD) is intended for the treatment of major traumatic haemorrhage only, and currently only as part of clinical studies in the pre-hospital situation, with transfusion of a maximum of 4 units (or weight-related equivalent for children) prior to switching to standard component therapy. During the study period it may also be used for the treatment of non-traumatic major haemorrhage in patients who are blood group O and who require both red cells and plasma for treatment of bleeding, using the above dose.

- A unit of whole blood collected in the UK currently consists of 470 mL ±10% of blood from a suitable donor (see Chapter 3), plus 63 mL of CPD anticoagulant, which is then LD, and stored in an approved container. The Eurobloodpack contains 66.5 mL of anticoagulant and is suitable for the collection of 475 mL ±10%, although in the UK a volume of 495 mL will not be exceeded.

- Donations of whole blood where the bleed time exceeded 15 minutes are not suitable for direct clinical use.

- Donations should be selected from male donors as a TRALI risk reduction measure.

- The component should be made from group O RhD negative, Kell negative donations.

- The component should be free from clinically significant irregular blood group antibodies including high-titre anti-A and anti-B.

- Red Cells and Plasma, LD, should be administered through a CE marked transfusion set.

Dr Sheila MacLennan
Professional Director - Joint UKBTS Professional Advisory Committee

Direct Dial: (0113) 820 8638  sheila.maclennan@nhsbt.nhs.uk